Does the WHO 2010 classification of pancreatic neuroendocrine neoplasms accurately characterize pancreatic neuroendocrine carcinomas?

Journal of Gastroenterology

Volumn 50, Issue 5, 2015, Pages 564-572

  Hijioka, Susumu ^a   Hosoda, Waki ^a   Mizuno, Nobumasa ^a   Hara, Kazuo ^a   Imaoka, Hiroshi ^a   Bhatia, Vikram ^b   Mekky, Mohamed A ^c   Tajika, Masahiro ^a   Tanaka, Tsutomu ^a   Ishihara, Makoto ^a   Yogi, Tatsuji ^a   Tsutumi, Hideharu ^a   Fujiyoshi, Toshihisa ^a   Sato, Takamitsu ^a   Hieda, Nobuhiro ^a   Yoshida, Tsukasa ^a   Okuno, Nozomi ^a   Shimizu, Yasuhiro ^a   Yatabe, Yasushi ^a   Niwa, Yasumasa ^a   Yamao, Kenji ^a   more..

^a AICHI CANCER CENTER HOSPITAL   (Japan)

^b INSTITUTE OF LIVER AND BILIARY SCIENCES   (India)

^c ASSIUT UNIVERSITY   (Egypt)

Author keywords

Ki67 labeling index; KRAS mutation; Neuroendocrine carcinoma; WHO classification

Indexed keywords

CHROMOGRANIN A; CISPLATIN; ETOPOSIDE; EVEROLIMUS; GEMCITABINE; IRINOTECAN; K RAS PROTEIN; KI 67 ANTIGEN; RETINOBLASTOMA PROTEIN; SYNAPTOPHYSIN; KRAS PROTEIN, HUMAN; PROTEIN P21; TUMOR MARKER;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURGERY; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DRUG RESPONSE; FEMALE; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LARGE CELL NEUROENDOCRINE CARCINOMA; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTIDETECTOR COMPUTED TOMOGRAPHY; ONCOGENE K RAS; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREATIC NEUROENDOCRINE CARCINOMA; PANCREATIC NEUROENDOCRINE TUMOR; POORLY DIFFERENTIATED NEUROENDOCRINE CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SMALL CELL CARCINOMA; SMALL CELL NEUROENDOCRINE CARCINOMA; SYMPTOM; TUMOR LOCALIZATION; TUMOR VOLUME; WELL DIFFERENTIATED NEUROENDOCRINE CARCINOMA; WORLD HEALTH ORGANIZATION; CANCER GRADING; CANCER STAGING; CARCINOMA, NEUROENDOCRINE; CLASSIFICATION; ENDOSCOPIC ULTRASOUND GUIDED FINE NEEDLE BIOPSY; EVALUATION STUDY; GENETICS; MORTALITY; MUTATION; PANCREATIC NEOPLASMS; PATHOLOGY; PROGNOSIS; REPRODUCIBILITY;

ADULT; AGED; BIOMARKERS, TUMOR; CARCINOMA, NEUROENDOCRINE; ENDOSCOPIC ULTRASOUND-GUIDED FINE NEEDLE ASPIRATION; FEMALE; HUMANS; KI-67 ANTIGEN; MALE; MIDDLE AGED; MUTATION; NEOPLASM GRADING; NEOPLASM STAGING; PANCREATIC NEOPLASMS; PROGNOSIS; PROTO-ONCOGENE PROTEINS P21(RAS); REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; WORLD HEALTH ORGANIZATION;

EID: 84928997181     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-014-0987-2     Document Type: Article

References (31)

1. Pape UF, Jann H, Muller-Nordhorn J, et al. Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors. Cancer. 2008;113:256–65.
2. Bosman F, Carneiro F, Hruban RH, et al. WHO classification of tumours of the digestive system. Lyon, France: IARC Press; 2010.
3. Rindi G, Klöppel G, Alhman H, et al. TNM staging of foregut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Arch. 2006;449:395–401.
4. Moertel CG, Kvols LK, O’Connell MJ, et al. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer. 1991;68:227–32.
5. Mitry E, Baudin E, Ducreux M, et al. Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin. Br J Cancer. 1999;81:1351–5.
6. Pavel M, Baudin E, Couvelard A, et al. ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology. 2012;95:157–76.
7. Velayoudom-Cephise FL, Duvillard P, Foucan L, et al. Are G3 ENETS neuroendocrine neoplasms heterogeneous? Endoc-Relat Cancer. 2013;20:649–57.
8. Basturk O, Tang L, Hruban RH, et al. Poorly differentiated neuroendocrine carcinomas of the pancreas: a clinicopathologic analysis of 44 cases. Am J Surg Pathol. 2014;38:437–47.
9. Sorbye H, Welin S, Langer SW, et al. Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study. Ann Oncol: Off J Eur Soc Med Oncol/ESMO. 2013;24:152–60.
10. Yachida S, Vakiani E, White CM, et al. Small cell and large cell neuroendocrine carcinomas of the pancreas are genetically similar and distinct from well-differentiated pancreatic neuroendocrine tumors. Am J Surg Pathol. 2012;36:173–84.
11. Hijioka S, Matsuo K, Mizuno N, et al. Role of endoscopic ultrasound and endoscopic ultrasound-guided fine-needle aspiration in diagnosing metastasis to the pancreas: a tertiary center experience. Pancreatol: Off J Int Assoc Pancreatol. 2011;11:390–8.
12. Rindi G, Kloppel G, Alhman H, et al. TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Archiv: Int J Pathol. 2006;449:395–401.
13. Plockinger U, Rindi G, Arnold R, et al. Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. A consensus statement on behalf of the European Neuroendocrine Tumour Society (ENETS). Neuroendocrinology. 2004;80:394–424.
14. Haba S, Yamao K, Bhatia V, et al. Diagnostic ability and factors affecting accuracy of endoscopic ultrasound-guided fine needle aspiration for pancreatic solid lesions: Japanese large single center experience. J Gastroenterol. 2013;48:973–81.
15. Hasegawa T, Yamao K, Hijioka S, et al. Evaluation of Ki-67 index in EUS-FNA specimens for the assessment of malignancy risk in pancreatic neuroendocrine tumors. Endoscopy. 2014;46:32–8.
16. Hosoda W, Takagi T, Mizuno N, et al. Diagnostic approach to pancreatic tumors with the specimens of endoscopic ultrasound-guided fine needle aspiration. Pathol Int. 2010;60:358–64.
17. Yatabe Y, Hida T, Horio Y, et al. A rapid, sensitive assay to detect EGFR mutation in small biopsy specimens from lung cancer. J Mol Diagn. 2006;8:335–41.
18. Rodallec M, Vilgrain V, Couvelard A, et al. Endocrine pancreatic tumours and helical CT: contrast enhancement is correlated with microvascular density, histoprognostic factors and survival. Pancreatol: Off J Int Assoc Pancreatol. 2006;6:77–85.
19. d’Assignies G, Couvelard A, Bahrami S, et al. Pancreatic endocrine tumors: tumor blood flow assessed with perfusion CT reflects angiogenesis and correlates with prognostic factors1. Radiology. 2009;250:407–16.
20. Jiao Y, Shi C, Edil BH, et al. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science. 2011;331:1199–203.
21. Nassar H, Albores-Saavedra J, Klimstra DS. High-grade neuroendocrine carcinoma of the ampulla of vater: a clinicopathologic and immunohistochemical analysis of 14 cases. Am J Surg Pathol. 2005;29:588–94.
22. Parwani AV, Geradts J, Caspers E, et al. Immunohistochemical and genetic analysis of non-small cell and small cell gallbladder carcinoma and their precursor lesions. Mod Pathol: Off J USA Can Acad Pathol Inc. 2003;16:299–308.
23. Fonseca PJ, Uriol E, Galván JA, et al. Prolonged clinical benefit of Everolimus therapy in the management of high-grade pancreatic neuroendocrine carcinoma. Case Rep Oncol. 2013;6:441–9.
24. Ogura T, Yamao K, Sawaki A, et al. Clinical impact of K-ras mutation analysis in EUS-guided FNA specimens from pancreatic masses. Gastrointest Endosc. 2012;75:769–74.
25. Ito T, Igarashi H, Nakamura K, et al. Epidemiological trends of pancreatic and gastrointestinal neuroendocrine tumors in Japan: a nationwide survey analysis. J Gastroenterol. 2014. doi:10.1007/s00535-014-0934-2.
26. Barton CM, McKie AB, Hogg A, et al. Abnormalities of the RB1 and DCC tumor suppressor genes: uncommon in human pancreatic adenocarcinoma. Mol Carcinog. 1995;13:61–9.
27. Gerdes B, Ramaswamy A, Ziegler A, et al. p16INK4a is a prognostic marker in resected ductal pancreatic cancer: an analysis of p16INK4a, p53, MDM2, an Rb. Ann Surg. 2002;235:51–9.
28. Weynand B, Borbath I, Bernard V, et al. Pancreatic neuroendocrine tumour grading on endoscopic ultrasound-guided fine needle aspiration: high reproducibility and inter-observer agreement of the Ki-67 labelling index. Cytopathology. 2013. doi:10.1111/cyt.12111.
29. Piani C, Franchi GM, Cappelletti C, et al. Cytological Ki-67 in pancreatic endocrine tumours: an opportunity for pre-operative grading. Endocr Relat Cancer. 2008;15:175–81.
30. Larghi A, Capurso G, Carnuccio A, et al. Ki-67 grading of nonfunctioning pancreatic neuroendocrine tumors on histologic samples obtained by EUS-guided fine-needle tissue acquisition: a prospective study. Gastrointest Endosc. 2012;76:570–7.
31. Chatzipantelis P, Konstantinou P, Kaklamanos M, et al. The role of cytomorphology and proliferative activity in predicting biologic behavior of pancreatic neuroendocrine tumors: a study by endoscopic ultrasound-guided fine-needle aspiration cytology. Cancer. 2009;117:211–6.